JMJD3 Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-JMJD3 antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | JMJD3 |
| Clone | polyclonal |
| Host Species | Rabbit |
| Reactive Species | human, monkey |
| Isotype | n/a |
| Format | affinity purified |
| Size | 0.1 mg |
| Concentration | 0.50 ug/ul in antibody stabilization buffer |
| Applications | ELISA (EIA), Immunoprecipitation (IP), Western Blot (WB) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Specificity: Cross reactive to isotypes of 3C only. Overview: Histone demethylase that specifically demethylates 'Lys-9' and 'Lys-36' residues of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-4', H3 'Lys-27' nor H4 'Lys-20'. Demethylates trimethylated H3 'Lys-9' and H3 'Lys-36' residue, while it has no activity on mono- and dimethylated residues. Demethylation of Lys residue generates formaldehyde and succinate.Structure: Overexpressed in several esophageal squamous cell carcinomas (ESCs).Expression: Nucleus |
| Immunogen | Immunogen: Synthetic peptide taken within amino acid region 500-550 on JmjC domain-containing histone demthylation protein 3C. Conjugation: Unconjugated |
| Other Names | [Affinity Purified JmjC domain-containing histone demthylation protein 3C; Histone demethylase JMJD3; JmjC domain containing protein 3; Jumonji D3; Jumonji domain containing 3; Kdm6b; KIAA0346; Lysine demethylase 6B] |
| Gene, Accession # | [JMJD3], Gene ID: 23081, NCBI: NP_001140167.1, UniProt: Q9H3R0 |
| Catalog # | MBS5400459 |
| Price | $390 |
| Order / More Info | JMJD3 Antibody from MYBIOSOURCE INC. |
| Product Specific References | n/a |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies